ProMetic Life Sciences (OTCMKTS:PFSCF – Get Free Report) and Pharmaxis (OTCMKTS:PXSLY – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, analyst recommendations and risk. Profitability This table compares ProMetic Life Sciences […]
10 choses à savoir mardi lesaffaires.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lesaffaires.com Daily Mail and Mail on Sunday newspapers.
Esbriet, and Ofev (tyrosine kinase inhibitors). Both drugs have been shown to slow the disease progression but do not significantly impact mortality.
The surge in Idiopathic Pulmonary Fibrosis market size is due to an increase in the prevalence of IPF patients in the 7MM, along with promising assets such as
RG 6354, Pamrevlumab,
Of all the emerging therapies, the most anticipated product to launch is the
RG 6354 (Roche). It has received Breakthrough Therapy Designation from the FDA. Apart from this, other products such as
Pamrevlumab,
, Ziritaxestat, GB0139, and others have demonstrated early promising results.
The IPF market will experience a boost in market growth owing to the factors such as the market entry of novel therapies aided by the grant given by the special regulatory designations, an increase in the aging population, and an increase in the prevalence of fibrotic diseases in those population. However, the poor prognosis of IPF patients, lack of curative